Actavia Life Sciences, Inc. 是一家生物技术公司,致力于开发用于治疗白血病和淋巴瘤疾病的疗法。公司总部位于纽约州纽约市,目前拥有1名全职员工。该公司于2014年3月28日上市。公司致力于开发治疗方法,以满足急性髓系白血病(AML)及其他类型白血病和淋巴瘤尚未满足的医疗需求。AML通常是一种老年人疾病。公司正在开发靶向LSD1基因的小分子药物候选物,该基因控制着AML亚型发病机制的相关通路。其RASP-201是一种新型口服、选择性可逆的赖氨酸特异性去甲基化酶(LSD1)抑制剂,该通路会阻断细胞分化并导致AML预后不良。在AML小鼠模型中,口服RASP-201显示出体内治疗效果。其主要适应症为AML,该病可能在数周至数月内致命。
RASP stock price ended at $0 on 星期五, after dropping 100.00%
On the latest trading day Dec 26, 2025, the stock price of RASP fell by 100.00%, dropping from $0.00 to $0.00. During the session, the stock saw a volatility of NaN%, with prices oscillating between a daily low of $0.00 and a high of $0.00. On the latest trading day, the trading volume for RASP rose by 19.6K shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 20.0K shares were traded, with a market value of approximately --.